

SUMMARY OF PRODUCT CHARACTERISTICS (SPC)

1. NAME OF THE MEDICINAL PRODUCT

MOXICOR CAPSULES (Amoxicillin 250mg Capsules)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each hard gelatin capsule contains amoxicillin trihydrate equivalent to 250mg amoxicillin

For a full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Capsule

Hard gelatin capsule having grey coloured cap and yellow coloured body containing almost white powder.

4. CLINICAL PARTICULARS

4.1 Therapeutic Indications:

Amoxicillin is indicated for the treatment of the following infections in adults and children (see section 4.2, 4.4 and 5.1).

- Acute bacterial sinusitis
- Acute streptococcal tonsillitis and pharyngitis
- Acute exacerbations of chronic bronchitis
- Community acquired pneumonia
- Acute otitis media
- Acute cystitis
- Acute pyelonephritis
- Asymptomatic Bacteriuria in pregnancy
- Typhoid and paratyphoid fevers
- Dental abscess with spreading cellulitis
- Prosthetic joint infections
- Helicobacter pylori eradication
- Lyme disease

Amoxicillin is also indicated for the prophylaxis of endocarditis. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2 Posology and Method of Administration:

Posology

The dose of Amoxicillin that is selected to treat an individual infection should take into account:

- The expected pathogens and their likely susceptibility to antibacterial agents (see section 4.4)
- The severity and the site of infection
- The age, weight and renal function of the patient; as shown below

The duration of therapy should be determined by the type of infection and the response of the patient, and should generally be as short as possible. Some infections require longer periods of treatment (see section 4.4 regarding prolonged therapy).

Adults and children ≥ 40 kg

Indication*	Dose*
Acute bacterial sinusitis	250mg to 500mg every 8 hours or 750mg to 1g every 12 hours
Asymptomatic bacteriuria in pregnancy	
Acute pyelonephritis	For severe infections 750mg to 1g every 8 hours
Dental abscess with spreading cellulitis	Acute cystitis may be treated with 3g twice daily for one day
Acute cystitis	
Acute otitis media	500mg every 8 hours, 750mg to 1g every 12 hours
Acute streptococcal tonsillitis and pharyngitis	For severe infections 750mg to 1g every 8 hours for 10 days
Acute exacerbations of chronic bronchitis	
Community acquired pneumonia	500 mg to 1 g every 8 hours
Typhoid and paratyphoid fever	500 mg to 2 g every 8 hours
Prosthetic joint infections	500 mg to 1 g every 8 hours
Prophylaxis of endocarditis	2 g orally, single dose 30 to 60 minutes before procedure
<i>Helicobacter pylori</i> eradication	750mg to 1g twice daily in combination with a proton pump inhibitor (e.g. omeprazole, lansoprazole) and another antibiotic (e.g.

	clarithromycin, metronidazole) for 7 days
Lyme disease (see section 4.4)	Early stage: 500mg to 1g every 8 hours up to a maximum of 4 g/day in divided doses for 14 days (10 to 21 days) Late stage (systemic involvement): 500mg to 2g every 8 hours up to a maximum of 6 g/day in divided doses for 10 to 30 days
*Consideration should be given to the official treatment guidelines for each indication	

Children <40 kg

Children may be treated with Amoxicillin capsules, dispersible tablets, suspensions or sachets.

Amoxicillin Paediatric Suspension is recommended for children under six months of age.

Children weighing 40kg or more should be prescribed the adult dosage.

Recommended doses:

Indication⁺	Dose⁺
Acute bacterial sinusitis	20 to 90 mg/kg/day in divided doses*
Acute otitis media	
Community acquired pneumonia	
Acute cystitis	
Acute pyelonephritis	
Dental abscess with spreading cellulitis	
Acute streptococcal tonsillitis and pharyngitis	40 to 90 mg/kg/day in divided doses*
Typhoid and paratyphoid fever	100 mg/kg/day in three divided doses
Prophylaxis of endocarditis	50 mg/kg orally, single dose 30 to 60 minutes before procedure
Lyme disease (see section 4.4)	Early stage: 25 to 50 mg/kg/day in three divided doses for 10 to 21 days Late stage (systemic involvement): 100 mg/kg/day in three divided doses for 10 to 30 days

+ Consideration should be given to the official treatment guidelines for each indication.

*Twice daily dosing regimens should only be considered when the dose is in the upper range.

Elderly

No dose adjustment is considered necessary.

Renal impairment

GFR (ml/min)	Adults and children \geq 40 kg	Children < 40 kg [#]
greater than 30	No adjustment necessary	No adjustment necessary
10 to 30	Maximum 500 mg twice daily	15 mg/kg given twice daily (maximum 500 mg twice daily)
less than 10	Maximum 500 mg/day.	15 mg/kg given as a single dose (maximum 500 mg)

[#] In the majority of cases, parenteral therapy is preferred.

In patients receiving haemodialysis

Amoxicillin may be removed from the circulation by haemodialysis

	Haemodialysis
Adults and children over 40 kg	500mg every 24h Prior to haemodialysis one additional dose of 500mg should be administered. In order to restore circulating blood levels, another dose of 500mg should be administered after haemodialysis
Children under 40 kg	15 mg/kg/day given as a single daily dose (maximum 500mg). Prior to haemodialysis one additional dose of 15 mg/kg should be administered. In order to restore circulating blood levels, another dose of 15 mg/kg should be administered after haemodialysis

In patients receiving peritoneal dialysis

Amoxicillin maximum 500mg/day

Hepatic impairment

Dose with caution and monitor hepatic function at regular intervals (see section 4.4 and 4.8).

Method of administration

Amoxicillin is for oral use.

Absorption of amoxicillin is unimpaired by food.

Therapy can be started parenterally according to the dosing recommendations of the intravenous formulation and continued with an oral preparation.

Swallow with water without opening capsule.

4.3 Contraindication:

Hypersensitivity to the active substance, to any of the penicillins or to any of the excipients listed in section 6.1.

History of a severe immediate hypersensitivity reaction (e.g. anaphylaxis) to another beta-lactam agent (e.g. a cephalosporin, carbapenem or monobactam).

4.4 Special Warnings and Precautions for Use:

Hypersensitivity reactions

Before initiating therapy with amoxicillin, careful enquiry should be made concerning previous hypersensitivity reactions to penicillin and cephalosporins or other beta-lactam agents (see sections 4.3 and 4.8).

Serious and occasionally fatal hypersensitivity reactions (including anaphylactoid and severe cutaneous adverse reactions) have been reported in patients on penicillin therapy.

Hypersensitivity reactions can also progress to Kounis syndrome, a serious allergic reaction that can result in myocardial infarction (see section 4.8). These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and in atopic individuals. If an allergic reaction occurs, amoxicillin therapy must be discontinued and appropriate alternative therapy instituted.

Drug-induced enterocolitis syndrome (DIES) has been reported mainly in children receiving amoxicillin (see section 4.8). DIES is an allergic reaction with the leading symptom of protracted vomiting (1-4 hours after drug intake) in the absence of allergic skin or respiratory symptoms. Further symptoms could comprise abdominal pain, diarrhoea, hypotension or leucocytosis with neutrophilia. There have been severe cases including progression to shock.

Non-susceptible microorganisms

Amoxicillin is not suitable for the treatment of some types of infection unless the pathogen is already documented and known to be susceptible or there is a very high likelihood that the pathogen would be suitable for treatment with amoxicillin (see section 5.1). This particularly applies when considering the treatment of patients with urinary tract infections and severe infections of the ear, nose and throat.

Convulsions

Convulsions may occur in patients with impaired renal function or in those receiving high doses or in patients with predisposing factors (e.g. history of seizures, treated epilepsy or meningeal disorders (see section 4.8).

Renal impairment

In patients with renal impairment, the dose should be adjusted according to the degree of impairment (see section 4.2).

Skin reactions

The occurrence at the treatment initiation of a feverish generalised erythema associated with pustula may be a symptom of acute generalised exanthemous pustulosis (AGEP, see section 4.8). This reaction requires amoxicillin discontinuation and contra-indicates any subsequent administration.

Amoxicillin should be avoided if infectious mononucleosis is suspected since the occurrence of a morbilliform rash has been associated with this condition following the use of amoxicillin.

Jarisch-Herxheimer reaction

The Jarisch-Herxheimer reaction has been seen following amoxicillin treatment of Lyme disease (see section 4.8). It results directly from the bactericidal activity of amoxicillin on the causative bacteria of Lyme disease, the spirochaete *Borrelia burgdorferi*. Patients should be reassured that this is a common and usually self-limiting consequence of antibiotic treatment of Lyme disease.

Overgrowth of non-susceptible microorganisms

Prolonged use of may occasionally result in overgrowth of non-susceptible organisms (superinfection).

Antibiotic-associated colitis has been reported with nearly all antibacterial agents and may range in severity from mild to life threatening (see section 4.8). Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during, or subsequent to, the administration of any antibiotics. Should antibiotic-associated colitis occur, amoxicillin should immediately be discontinued, a physician consulted and an appropriate therapy initiated. Anti-peristaltic medicinal products are contra-indicated in this situation.

Prolonged therapy

Periodic assessment of organ system functions; including renal, hepatic and haematopoietic function is advisable during prolonged therapy. Elevated liver enzymes and changes in blood counts have been reported (see section 4.8)

Crystalluria

In patients with reduced urine output, crystalluria (including acute renal injury) has been observed very rarely, predominantly with parenteral therapy. During the administration of high doses of amoxicillin, it is advisable to maintain adequate fluid intake and urinary output in order to reduce the possibility of amoxicillin crystalluria. In patients with bladder catheters, a regular check of patency should be maintained (see sections 4.8 and 4.9).

Anticoagulants

Prolongation of prothrombin time has been reported rarely in patients receiving amoxicillin. Appropriate monitoring should be undertaken when anticoagulants are prescribed

concomitantly. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation (see section 4.5 and 4.8)

Interference with diagnostic tests

Elevated serum and urinary levels of amoxicillin are likely to affect certain laboratory tests. Due to high urinary concentrations of amoxicillin, false positive readings are common with chemical methods.

It is recommended that when testing for the presence of glucose in urine during amoxicillin treatment, enzymatic glucose oxidase methods should be used.

The presence of amoxicillin may distort assay results for oestriol in pregnant women.

4.5 Interaction with Other Medicinal Products and Other Forms of Interaction:

Oral anticoagulants

Oral anticoagulants and penicillin antibiotics have been widely used in practice without reports of interaction. However, in the literature there are rare cases of increased international normalised ratio in patients maintained on acenocoumarol or warfarin and prescribed a course of amoxicillin. If co-administration is necessary, the prothrombin time or international normalised ratio should be carefully monitored with the addition or withdrawal of amoxicillin. Moreover, adjustments in the dose of oral anticoagulants may be necessary (see sections 4.4 and 4.8).

Probenecid

Concomitant use of probenecid is not recommended. Probenecid decreases the renal tubular secretion of amoxicillin. Concomitant use of probenecid may result in increased and prolonged blood levels of amoxicillin

Allopurinol

Concurrent administration of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions.

Tetracyclines

Tetracyclines and other bacteriostatic drugs may interfere with the bactericidal effects of amoxicillin.

Methotrexate

Penicillins may reduce the excretion of methotrexate causing a potential increase in toxicity.

4.6 Fertility, Pregnancy and Lactation:

Pregnancy:

Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. Limited data on the use of amoxicillin during pregnancy in humans do not indicate an increased risk of congenital malformations. Amoxicillin may be used in pregnancy when the potential benefits outweigh the potential risks associated with treatment.

Breast-feeding:

Amoxicillin is excreted into breast milk in small quantities with the possible risk of sensitisation. Consequently, diarrhoea and fungus infection of the mucous membranes are possible in the breast-fed infant, so that breast-feeding might have to be discontinued. Amoxicillin should only be used during breast-feeding after benefit/risk assessment by the physician in charge.

Fertility:

There are no data on the effects of amoxicillin on fertility in humans. Reproductive studies in animals have shown no effects on fertility.

4.7 Effects on Ability to Drive and Use Machines:

No studies on the effects on the ability to drive and use machines have been performed. However, undesirable effects may occur (e.g. allergic reactions, dizziness, convulsions), which may influence the ability to drive and use machines (see section 4.8).

4.8 Undesirable Effects:

The most commonly reported adverse drug reactions (ADRs) are diarrhoea, nausea and skin rash.

The ADRs derived from clinical studies and post-marketing surveillance with amoxicillin, presented by MedDRA System Organ Class are listed below.

The following terminologies have been used in order to classify the occurrence of undesirable effects:

Very common ($\geq 1/10$),

Common ($\geq 1/100$ to $< 1/10$),

Uncommon ($\geq 1/1000$ to $< 1/100$),

Rare ($\geq 1/10,000$ to $< 1/1,000$),

Very rare ($< 1/10,000$),

Not known (cannot be estimated from the available data)

<u>Infections and infestations</u>	
Very rare	Mucocutaneous candidiasis
<u>Blood and lymphatic system disorders</u>	
Very rare	Reversible leucopenia (including severe neutropenia or agranulocytosis), reversible thrombocytopenia and haemolytic anaemia.

	Prolongation of bleeding time and prothrombin time (see section 4.4).
<u>Immune system disorders</u>	
Very rare	Severe allergic reactions, including angioneurotic oedema, anaphylaxis, serum sickness and hypersensitivity vasculitis (see section 4.4).
Not known	Jarisch-Herxheimer reaction (see section 4.4).
<u>Nervous system disorders</u>	
Very rare	Hyperkinesia, dizziness, convulsions (see section 4.4).
Not known	Aseptic meningitis
<u>Gastrointestinal disorders</u>	
<i>Clinical Trial Data</i>	
*Common	Diarrhoea and nausea
*Uncommon	Vomiting
<i>Post-marketing Data</i>	
Very rare	Antibiotic associated colitis (including pseudomembraneous colitis and haemorrhagic colitis see section 4.4). Black hairy tongue
Not Known	Drug-induced enterocolitis syndrome
<u>Hepatobiliary disorders</u>	
Very rare	Hepatitis and cholestatic jaundice. A moderate rise in AST and/or ALT.
<u>Skin and subcutaneous tissue disorders</u>	
<i>Clinical Trial Data</i>	
*Common	Skin rash
*Uncommon	Urticaria and pruritus
<i>Post-marketing Data</i>	
Very rare	Skin reactions such as erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous and exfoliative dermatitis, acute generalised exanthematous pustulosis (AGEP) (see section 4.4), and drug reaction with eosinophilia and systemic symptoms (DRESS).
Not known	Linear IgA disease
<u>Renal and urinary tract disorders</u>	

Very rare	Interstitial nephritis
Not Known	Crystalluria (including acute renal injury)
<u>Cardiac disorders</u>	
Not known	Kounis syndrome
* The incidence of these AEs was derived from clinical studies involving a total of approximately 6,000 adult and paediatric patients taking amoxicillin.	

4.9 Overdose:

Symptoms and signs of overdose

Gastrointestinal symptoms (such as nausea, vomiting and diarrhoea) and disturbances of the fluid and electrolyte balances may be evident. Amoxicillin crystalluria, in some cases leading to renal failure, has been observed (see Section 4.4). Convulsions may occur in patients with impaired renal function or in those receiving high doses (see section 4.4 and 4.8).

Treatment of intoxication

Gastrointestinal symptoms may be treated symptomatically, with attention to the water/electrolyte balance.

Amoxicillin can be removed from the circulation by haemodialysis.

Amoxicillin crystalluria, in some cases leading to renal failure, has been observed (see section 4.4).

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic Properties:

Pharmacotherapeutic group: penicillins with extended spectrum; ATC code: J01CA04

Mechanism of action

Amoxicillin is a semisynthetic penicillin (beta-lactam antibiotic) that inhibits one or more enzymes (often referred to as penicillin-binding proteins, PBPs) in the biosynthetic pathway of bactericidal peptidoglycan, which is an integral structural component of the bacterial cell wall. Inhibition of peptidoglycan synthesis leads to weakening of the cell wall, which is usually followed by cell lysis and death.

Amoxicillin is susceptible to degradation by beta-lactamases produced by resistant bacteria and therefore the spectrum of activity of amoxicillin alone does not include organisms which produce these enzymes.

Pharmacokinetic/ pharmacodynamic relationship

The time above the minimum inhibitory concentration (T>MIC) is considered to be the major determinant of efficacy for amoxicillin.

Mechanisms of resistance

The main mechanisms of resistance to amoxicillin are:

- Inactivation by bacterial beta-lactamases
- Alteration of PBPs, which reduce the affinity of the antibacterial agent for the target.

Impermeability of bacteria or efflux pump mechanisms may cause or contribute to bacterial resistance, particularly in Gram-negative bacteria.

Breakpoints

MIC breakpoints for amoxicillin are those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) version 5.0.

Organism	MIC breakpoint (mg/L)	
	Susceptible ≤	Resistant >
Enterobacteriaceae	8 ¹	8
<i>Staphylococcus</i> spp.	Note ²	Note ²
<i>Enterococcus</i> spp. ³	4	8
Streptococcus groups A, B, C and G	Note ⁴	Note ⁴
<i>Streptococcus pneumoniae</i>	Note ⁵	Note ⁵
Viridans group streptococci	0.5	2
<i>Haemophilus influenzae</i>	2 ⁶	2 ⁶
<i>Moraxella catarrhalis</i>	Note ⁷	Note ⁷
<i>Neisseria meningitidis</i>	0.125	1
Gram positive anaerobes except <i>Clostridium difficile</i> ⁸	4	8
Gram negative anaerobes ⁸	0.5	2
<i>Helicobacter pylori</i>	0.125 ⁹	0.125 ⁹
<i>Pasteurella multocida</i>	1	1
Non-species related breakpoints ¹⁰	2	8
<p>1. Wild type Enterobacteriaceae are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild type isolates of <i>E. coli</i> and <i>P. mirabilis</i> as intermediate. When this is the case, use the MIC breakpoint $S \leq 0.5$ mg/L</p> <p>2. Most staphylococci are penicillinase producers, which are resistant to amoxicillin. Methicillin resistant isolates are, with few exceptions, resistant to all beta-lactam agents.</p> <p>3. Susceptibility to amoxicillin can be inferred from ampicillin</p> <p>4. The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility</p> <p>5. Breakpoints relate only to non-meningitis isolates. For isolates categorised as intermediate to ampicillin avoid oral treatment with amoxicillin. Susceptibility inferred from the MIC of ampicillin</p> <p>6. Breakpoints are based on intravenous administration. Beta-lactamase positive isolates should be reported resistant</p>		

7. Beta lactamase producers should be reported resistant
 8. Susceptibility to amoxicillin can be inferred from benzylpenicillin.
 9. The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.
 10. The non-species related breakpoints are based on doses of at least 0.5g x 3 or 4 doses daily (1.5 to 2 g/day).

The prevalence of resistance may vary geographically and with time for selected species, and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.

<i>In vitro</i> susceptibility of micro-organisms to Amoxicillin
Commonly Susceptible Species
<u>Gram-positive aerobes:</u> <i>Enterococcus faecalis</i> Beta-hemolytic streptococci (Groups A, B, C and G) <i>Listeria monocytogenes</i>
<u>Species for which acquired resistance may be a problem</u>
<u>Gram-negative aerobes:</u> <i>Escherichia coli</i> <i>Haemophilus influenzae</i> <i>Helicobacter pylori</i> <i>Proteus mirabilis</i> <i>Salmonella typhi</i> <i>Salmonella paratyphi</i> <i>Pasteurella multocida</i>
<u>Gram-positive aerobes:</u> Coagulase negative staphylococcus <i>Staphylococcus aureus</i> [‡] <i>Streptococcus pneumoniae</i> Viridans group streptococcus
<u>Gram-positive anaerobes:</u> <i>Clostridium</i> spp.
<u>Gram-negative anaerobes:</u> <i>Fusobacterium</i> spp.
<u>Other:</u> <i>Borrelia burgdorferi</i>
<u>Inherently resistant organisms</u> [†]
<u>Gram-positive aerobes:</u> <i>Enterococcus faecium</i> [†]
<u>Gram-negative aerobes:</u> <i>Acinetobacter</i> spp. <i>Enterobacter</i> spp. <i>Klebsiella</i> spp.

<i>Pseudomonas</i> spp.
<u>Gram-negative anaerobes:</u> <i>Bacteroides</i> spp. (many strains of <i>Bacteroides fragilis</i> are resistant)
<u>Others:</u> <i>Chlamydia</i> spp. <i>Mycoplasma</i> spp. <i>Legionella</i> spp.
† Natural intermediate susceptibility in the absence of acquired mechanism of resistance. ‡ Almost all <i>S.aureus</i> are resistant to amoxicillin due to production of penicillinase. In addition, all methicillin-resistant strains are resistant to amoxicillin.

5.2 Pharmacokinetic Properties:

Absorption

Amoxicillin fully dissociates in aqueous solution at physiological pH. It is rapidly and well absorbed by the oral route of administration. Following oral administration, amoxicillin is approximately 70% bioavailable. The time to peak plasma concentration (T_{max}) is approximately one hour.

The pharmacokinetic results for a study, in which an amoxicillin dose of 250 mg three times daily was administered in the fasting state to groups of healthy volunteers are presented below.

C _{max}	T _{max} [*]	AUC _(0-24h)	T _{1/2}
(µg/ml)	(h)	(µg.h/ml)	(h)
3.3 ± 1.12	1.5 (1.0-2.0)	26.7 ± 4.56	1.36 ± 0.56
*Median (range)			

In the range 250 to 3000 the bioavailability is linear in proportion to dose (measured as C_{max} and AUC). The absorption is not influenced by simultaneous food intake.

Haemodialysis can be used for elimination of amoxicillin.

Distribution

About 18% of total plasma amoxicillin is bound to protein and the apparent volume of distribution is around 0.3 to 0.41/kg.

Following intravenous administration, amoxicillin has been found in gall bladder, abdominal tissue, skin, fat, muscle tissue, synovial and peritoneal fluids, bile and pus. Amoxicillin does not adequately distribute into the cerebrospinal fluid.

From animal studies there is no evidence for significant tissue retention of drug-derived material. Amoxicillin, like most penicillins, can be detected in breast milk (see section 4.6)

Amoxicillin has been shown to cross the placental barrier (see section 4.6).

Biotransformation

Amoxicillin is partly excreted in the urine as the inactive penicilloic acid in quantities equivalent to up to 10 to 25% of the initial dose.

Elimination

The major route of elimination for amoxicillin is via the kidney.

Amoxicillin has a mean elimination half-life of approximately one hour and a mean total clearance of approximately 25 l/hour in healthy subjects. Approximately 60 to 70% of an orally administered dose is excreted unchanged in the urine during the first 6 hours after administration of a single 250mg or 500mg dose of amoxicillin. Various studies have found the urinary excretion to be 50-85% for amoxicillin over a 24 hour period.

Concomitant use of probenecid delays amoxicillin excretion (see section 4.5)

Age

The elimination half-life of amoxicillin is similar for children aged around 3 months to 2 years and older children and adults. For very young children (including preterm newborns) in the first week of life the interval of administration should not exceed twice daily administration due to immaturity of the renal pathway of elimination. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Gender

Following oral administration of amoxicillin to healthy males and female subjects, gender has no significant impact on the pharmacokinetics of amoxicillin.

Renal impairment

The total serum clearance of amoxicillin decreases proportionately with decreasing renal function (see section 4.2 and 4.4).

Hepatic impairment

Hepatically impaired patients should be dosed with caution and hepatic function monitored at regular intervals.

5.3 Preclinical Safety Data:

Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology, repeated dose toxicity, genotoxicity and toxicity to reproduction and development.

Carcinogenicity studies have not been conducted with amoxicillin.

6. PHARMACEUTICAL PARTICULARS

6.1 List of Excipients:

Hydrophobic Colloidal Anhydrous Silica

Magnesium Stearate

Purified Talc

Sodium Lauryl Sulfate

EHG Capsules Size "2" Grey /Yellow Plain IHS

6.2 Incompatibilities

None known

6.3 Shelf Life

36 Months

6.4 Special Precautions for Storage

Store below 30°C. Protect from light.

Keep Medicine out of reach of children.

6.5 Nature and Contents of Container:

Primary Packing: 10 Capsule to be packed in Alu - PVC blister.

Secondary Packing: Such 10 blister to be packed in a carton along with pack insert.

6.6 Special Precaution for Disposal and other handling:

Not applicable.

7. Marketing Authorization Holder:

CORAL LABORATORIES LIMITED

Plot No.27-28, Pharmacy, Selaqui, Dehradun, Uttarakhand, INDIA.

Phone : 91-0135-2698 422, 2698 466

Fax : 91-0135-2699 121

Email : doon@corallab.com, exports@corallab.com

8. MARKETING AUTHORIZATION NUMBERS

07611/09549/NMR/2022

9. DATE OF FIRST AUTHORIZATION/RENEWAL OF THE AUTHORIZATION

05/08/2022

10. Date of revision of the text:

04/07/2023

11. REFERENCES